These results suggest that treatment strategies combining mTOR inhibitors and linsitinib warrant further investigation, although considering the heterogeneous expression of the main components of the IGF pathway in the different ACC samples, the apparently modest antiproliferative effects observed at a low concentration of these compounds as well as the potential limits of the used human cell lines as model of human ACC, caution is recommended before to move from the bench to the bedside. The gene discussed is MTOR; the disease is adrenal cortex carcinoma.